相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial
Ghassan K. Abou-Alfa et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Sorafenib A Review of its Use in Advanced Hepatocellular Carcinoma
Gillian M. Keating et al.
DRUGS (2009)
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo
Jun-Yan Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers
See-Hyoung Park et al.
CANCER BIOLOGY & THERAPY (2008)
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
Hironobu Minami et al.
CANCER SCIENCE (2008)
Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma
Raffaella Lazzarini et al.
CLINICAL CANCER RESEARCH (2008)
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53
See-Hyoung Park et al.
JOURNAL OF UROLOGY (2008)
Orally bioavailable potent soluble epoxide hydrolase inhibitors
Sung Hee Hwang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
p21 is a prognostic marker for renal cell carcinoma: Implications for novel therapeutic approaches
Robert H. Weiss et al.
JOURNAL OF UROLOGY (2007)
Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury
John M. Seubert et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2007)
p21 blocks irradiation-induced apoptosis downstream of mitochondria by inhibition of cyclin-dependent kinase-mediated caspase-9 activation
Dennis Sohn et al.
CANCER RESEARCH (2006)
Requirement for pre-existing of p21 to prevent doxorubicin-induced apoptosis through inhibition of caspase-3 activation
J. J. Tang et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2006)
Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors
Kara R. Schmelzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
p53 stabilization and transactivation by a von Hippel-Lindau protein
Jae-Seok Roe et al.
MOLECULAR CELL (2006)
The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function
XF Liu et al.
CELL BIOLOGY INTERNATIONAL (2006)
Kidney cancer: Identification of novel targets for therapy
RH Weiss et al.
KIDNEY INTERNATIONAL (2006)
An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension
JD Imig et al.
HYPERTENSION (2005)
Induction of p21WAF1 expression protects HT29 colon cancer cells from apoptosis induced by cryoinjury
RR Sharma et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Soluble epoxide hydrolase is a therapeutic target for acute inflammation
KR Schmelzer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
A Awada et al.
BRITISH JOURNAL OF CANCER (2005)
Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension
O Jung et al.
HYPERTENSION (2005)
Opinion - The role of apoptosis in cancer development and treatment response
JM Brown et al.
NATURE REVIEWS CANCER (2005)
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines
M Heim et al.
ANTI-CANCER DRUGS (2005)
Cytosolic p21 Waf1/Cip1 increases cell cycle transit in vascular smooth muscle cells
Y Dong et al.
CELLULAR SIGNALLING (2004)
DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay
MT Branham et al.
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS (2004)
P21 (Waf1/Cip1) as a therapeutic target in breast and other cancers
RH Weiss
CANCER CELL (2003)
Cytoplasmic p21Cip1/WAF1 regulates neurite remodeling by inhibiting Rho-kinase activity
H Tanaka et al.
JOURNAL OF CELL BIOLOGY (2002)
Mechanism of doxorubicin-induced cell death and expression profile analysis
S Lee et al.
BIOTECHNOLOGY LETTERS (2002)
AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival
Y Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension
JD Imig et al.
HYPERTENSION (2002)
Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast cancer:: association with prognosis
ZE Winters et al.
EUROPEAN JOURNAL OF CANCER (2001)
Proliferation, cell cycle and apoptosis in cancer
GI Evan et al.
NATURE (2001)
分享论文
